SEC Filing Summary: BioSig Technologies, Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. (not Streamex Corp.) on April 6, 2015, covering events occurring on March 31, 2015. The filing details the consummation of a fifth closing under a Unit Purchase Agreement dated December 19, 2014, involving the sale of unregistered equity securities to accredited investors.
Key Financial Metrics
The filing reports specific capital raise figures but does not provide operational financial metrics such as revenue, profit, cash flow, margins, or debt levels.
- Proceeds from March 31 Closing: $1,025,900
- Shares Issued (March 31): 410,360 shares of Common Stock
- Warrants Issued (March 31): 410,360 "A" Warrants ($2.50 exercise price) and 205,180 "B" Warrants ($3.75 exercise price)
- Total Proceeds (All Closings): $4,009,000 (including the sixth closing referenced in the text)
- Total Units Issued (All Closings): 29.831 units (Initial Investors) plus 10.259 units (Additional Investors)
Material Changes
The primary material change is the increase in outstanding equity and cash proceeds resulting from the fifth closing. The company issued an aggregate of 10.259 units to additional accredited investors. This transaction is part of a series of closings that began in December 2014, with previous closings reported on December 29, 2014, January 6, 2015, January 26, 2015, February 17, 2015, and March 5, 2015.
Guidance, Risks, and Unusual Items
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure regarding unregistered securities. The securities were sold in reliance on exemptions under Section 4(a)(2) and Regulation D (Rule 506) of the Securities Act of 1933. Investors are required to be accredited. The text notes that summaries of the Purchase Agreement and Registration Rights Agreement are qualified by reference to the full agreements filed as exhibits to the 2014 Form 10-K.
Investor Verification Checklist
- Verify the total number of outstanding shares and warrants post-issuance to assess dilution impact.
- Review the full text of the Unit Purchase Agreement and Registration Rights Agreement filed as exhibits to the 2014 Form 10-K for specific terms and conditions.
- Confirm the status of the "sixth closing" mentioned in the text to ensure the total proceeds figure of $4,009,000 is accurate and complete.
- Check subsequent filings for the use of proceeds and any changes in the company's capital structure.